作者：
Falchook,G.S. [1]
;
Lewis,K.D. [2]
;
Infante,J.R. [3]
;
Gordon,M.S. [4]
;
Vogelzang,N.J. [5]
;
DeMarini,D.J. [6]
;
Sun,P. [7]
;
Moy,C. [8]
;
Szabo,S.A. ;
Roadcap,L.T. ;
Peddareddigari,V.G.R. ;
Lebowitz,P.F. ;
Le,N.T. ;
Burris,H.A. ;
Messersmith,W.A. ;
O'Dwyer,P.J. ;
Kim,K.B. ;
Flaherty,K. ;
Bendell,J.C. ;
Gonzalez,R. ;
Kurzrock,R. ;
Fecher,L.A.
作者单位：
Division of Medical Oncology, University of Colorado School of Medicine, Aurora, CO, United States
[1]
Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas
[2]
GlaxoSmithKline Research and Development, Collegeville, PA, United States
[3]
University of Pennsylvania Abramson Cancer Center, Philadelphia, PA, United States
[4]
Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN, United States
[5]
Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States, US Oncology Research
[6]
Department of Melanoma Medical Oncology, Division of Cancer Medicine, University of Texas MD
[7]
Pinnacle Oncology Hematology, Scottsdale, AZ, United States
[8]
发布时间
2013-11-20
换一批
